For boron drug discovery using polymeric DDS targeting cell surface markers, there are reports of immunoliposomes containing an anti-EGFR antibody bound to the liposome surface and boron drug BSH for malignant brain tumors with high EGFR expression levels [38]. Here, EGFR is linked to brain cancer.